These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33841857)

  • 1. Efficacy of enoxaparin in preventing coagulation during high-flux haemodialysis, expanded haemodialysis and haemodiafiltration.
    Santos A; Macías N; Vega A; Abad S; Linares T; Aragoncillo I; Cruzado L; Pascual C; Goicoechea M; López-Gómez JM
    Clin Kidney J; 2021 Apr; 14(4):1120-1125. PubMed ID: 33841857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanded hemodialysis: Is anticoagulation of the dialysis circuit different from online hemodiafiltration and high-flux hemodialysis?
    Santos A; Macías N; Vega A; Abad S; Linares T; Aragoncillo I; Cruzado L; Pascual C; Goicoechea M; López-Gómez JM
    Ther Apher Dial; 2022 Feb; 26(1):147-153. PubMed ID: 33890717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of procoagulatory activity of haemodialysis, haemofiltration and haemodiafiltration with a polysulfone membrane (APS) and with different modes of enoxaparin anticoagulation.
    Klingel R; Schaefer M; Schwarting A; Himmelsbach F; Altes U; Uhlenbusch-Körwer I; Hafner G
    Nephrol Dial Transplant; 2004 Jan; 19(1):164-70. PubMed ID: 14671052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the injection of low-molecular weight heparin in the arterial vs. venous blood line for preventing extracorporeal circuit clotting during hemodialysis.
    Belmouaz M; Goussard G; Joly F; Grand F; Sibille A; Ecotiere L; Desport E; Bauwens M; Thierry A; Bridoux F
    Hemodial Int; 2022 Jul; 26(3):314-322. PubMed ID: 35014175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arterial line versus venous line administration of low molecular weight heparin, enoxaparin for prevention of thrombosis in the extracorporeal blood circuit of patients on haemodialysis or haemodiafiltration: A randomized cross-over trial.
    Kurtkoti J; Bose B; Hiremagalur B; Sun J; Cochrane T
    Nephrology (Carlton); 2016 Aug; 21(8):663-8. PubMed ID: 26609786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Removal of large middle molecules via haemodialysis with medium cut-off membranes at lower blood flow rates: an observational prospective study.
    Kim TH; Kim SH; Kim TY; Park HY; Jung KS; Lee MH; Jhee JH; Lee JE; Choi HY; Park HC
    BMC Nephrol; 2019 Dec; 21(1):2. PubMed ID: 31892319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the efficacy of a medium cut-off dialyser and comparison with other high-flux dialysers in conventional haemodialysis and online haemodiafiltration.
    García-Prieto A; Vega A; Linares T; Abad S; Macías N; Aragoncillo I; Torres E; Hernández A; Barbieri D; Luño J
    Clin Kidney J; 2018 Oct; 11(5):742-746. PubMed ID: 30288272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
    Lavaud S; Canivet E; Wuillai A; Maheut H; Randoux C; Bonnet JM; Renaux JL; Chanard J
    Nephrol Dial Transplant; 2003 Oct; 18(10):2097-104. PubMed ID: 13679486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
    Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
    Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The high-volume haemodiafiltration vs high-flux haemodialysis registry trial (H4RT): a multi-centre, unblinded, randomised, parallel-group, superiority study to compare the effectiveness and cost-effectiveness of high-volume haemodiafiltration and high-flux haemodialysis in people with kidney failure on maintenance dialysis using linkage to routine healthcare databases for outcomes.
    Caskey FJ; Procter S; MacNeill SJ; Wade J; Taylor J; Rooshenas L; Liu Y; Annaw A; Alloway K; Davenport A; Power A; Farrington K; Mitra S; Wheeler DC; Law K; Lewis-White H; Ben-Shlomo Y; Hollingworth W; Donovan J; Lane JA
    Trials; 2022 Jun; 23(1):532. PubMed ID: 35761367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical Value of Anti-Xa Activity in the Evaluation of Extracorporeal Circuit Anticoagulation during Haemodialysis: Results of a Cross-Sectional Single-Centre Study.
    Coene KLM; Dekker MJE; Kerskes MCHM; Hengst M; Schonck MJM; Konings CJAM; Scharnhorst V
    Nephron; 2017; 137(3):205-211. PubMed ID: 28817831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the anticoagulant effect of low-molecular-weight heparins based on the anti-Xa level during haemodialysis.
    Tao M; Zheng D; Liang X; Ye M; Liu Y; Li Y; Shen H; He Q
    Nephrology (Carlton); 2020 Sep; 25(9):723-729. PubMed ID: 31999031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How biocompatible haemodialysers can conquer the need for systemic anticoagulation even in post-dilution haemodiafiltration: a cross-over study.
    Vanommeslaeghe F; Josipovic I; Boone M; van der Tol A; Dhondt A; Van Biesen W; Eloot S
    Clin Kidney J; 2021 Jul; 14(7):1752-1759. PubMed ID: 34548919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of solute clearance using pulsatile push-pull dialysate flow for the Quanta SC+: A novel clinic-to-home haemodialysis system.
    Buckberry C; Hoenich N; Krieter D; Lemke HD; Rüth M; Milad JE
    PLoS One; 2020; 15(3):e0229233. PubMed ID: 32119698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Haemodiafiltration with Heat Sterilized High-Flux Polyphenylene HF Dialyzer in Reducing Free Light Chains in Patients with Myeloma Cast Nephropathy.
    Rousseau-Gagnon M; Agharazii M; De Serres SA; Desmeules S
    PLoS One; 2015; 10(10):e0140463. PubMed ID: 26466100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin use during dialysis sessions induces an increase in the antiangiogenic factor soluble Flt1.
    Lavainne F; Meffray E; Pepper RJ; Néel M; Delcroix C; Salama AD; Fakhouri F
    Nephrol Dial Transplant; 2014 Jun; 29(6):1225-31. PubMed ID: 24516233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study.
    Vandenbosch I; Dejongh S; Claes K; Bammens B; De Vusser K; Van Craenenbroeck A; Kuypers D; Evenepoel P; Meijers B
    Clin Kidney J; 2021 Aug; 14(8):1901-1907. PubMed ID: 34345413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-dilution haemodiafiltration and low-flux haemodialysis have dissimilar effects on platelets: a side study of CONTRAST.
    Gritters-van den Oever M; Grooteman MP; Bartels PC; Blankestijn PJ; Bots ML; van den Dorpel MA; Schoorl M; Schoorl M; Ter Wee PM; Nubé MJ
    Nephrol Dial Transplant; 2009 Nov; 24(11):3461-8. PubMed ID: 19561150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease.
    Rabindranath KS; Strippoli GF; Daly C; Roderick PJ; Wallace S; MacLeod AM
    Cochrane Database Syst Rev; 2006 Oct; (4):CD006258. PubMed ID: 17054289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dalteparin dosing in high-flux haemodialysis and haemodiafiltration.
    Sridharan S; Berdeprado J; Sivalingam M; Farrington K
    Nephron Clin Pract; 2012; 122(1-2):53-7. PubMed ID: 23548465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.